Subscribe to Newsletter

Content by Stephanie Vine:

Business & Regulation Standards & Regulation

Peter Marks Resigns from FDA

| Stephanie Vine | 3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr.

Manufacture Facilities

FDA Warning Letters: March 2025 Edition

| Stephanie Vine | 3 min read

Indian CDMO denies manufacturing drug, contract testing lab pulled up for deficiencies, and lessons learned from Sanofi’s warning letter.

Discovery & Development Drug Discovery

Fixing Faulty Splicing

| Stephanie Vine | 2 min read

How antisense oligonucleotides open up targeted approaches to rare disease treatment.

Discovery & Development Formulation

Schizophrenia and the Future of Long-Acting Therapeutics

| Stephanie Vine | 5 min read

Long-acting injectables help with adherence, but what if an unfolding pill could provide an oral option?

Business & Regulation Trends & Forecasts

Drugs to Watch in 2025: Part 2

| Stephanie Vine | 9 min read

We take a deep dive into key industry trends off the back of Clarivate’s Drugs to Watch 2025 report

Business & Regulation Trends & Forecasts

Drugs to Watch in 2025: Part 1

| Stephanie Vine | 8 min read

We speak with Clarivate about their report listing eleven key drugs to watch in 2025.

Discovery & Development Drug Delivery

The Force Meets Oligonucleotides

| Stephanie Vine

Researchers develop a new platform to improve delivery of oligonucleotide therapies to muscle.

Discovery & Development Drug Discovery

Breaking Through Rare Diseases

| Stephanie Vine | 8 min read

We asked three rare disease drug developers about their work, the challenges facing the field, and what they would do with unlimited funds.

Manufacture Advanced Medicine

The Risks and Rewards of Rare Diseases

| Stephanie Vine | 4 min read

Bluebird bio’s financial situation is a stark reminder of the challenges of developing advanced therapies for rare diseases.

Business & Regulation Business Practice

Where Does All the Profit Go?

| Stephanie Vine | 2 min read

To shareholders – according to an analysis of financial reports from healthcare companies.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register

May Issue of The Medicine Maker